Board recommended a final dividend of Re. 0.10/- per share subject to the approval of the members at the ensuing AGM
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited financial results for Q4 and FY25, with standalone revenue rising ~21% to Rs. 1,483.91 lakhs and consolidated revenue growing ~8.5% to Rs. 3,696.37 lakhs. Consolidated profit after tax for FY25 stood at Rs. 99.38 lakhs versus Rs. 94.77 lakhs in FY24, a modest increase of about 5%. The board recommended a token final dividend of Re. 0.10 per share, pending shareholder approval at the AGM. The company also appointed new Internal Auditors (MGR & Co.) for FY26 and Secretarial Auditors (Manoj Parakh & Associates) for a 5-year term. An Independent Director resigned citing business commitments, and a new Independent Director was appointed in his place. The statutory auditor issued an unqualified opinion but flagged that sundry debtors and creditors of about Rs. 1,959.74 lakhs were adjusted via book entries between the company and its subsidiary without actual realization.
The small dividend and minor profit growth offer little excitement for shareholders, while the auditor's note on Rs. 19.6 crore of book-entry adjustments with the subsidiary and persistently negative operating cash flows raise governance and cash quality concerns. Investors should watch the related-party concentration (over half of sales routed through the subsidiary) and rising borrowings, which could weigh on the stock despite the clean audit opinion.